35070-82-7

Usage

Appearance

White to light yellow crystalline solid The compound forms solid crystals that are white to light yellow in color.

Common use

Intermediate in the synthesis of organic compounds It is primarily used as a starting material or intermediate in the production of other organic compounds.

Applications

Pharmaceutical and agrochemical industries The compound serves as a building block for the production of various drugs and pesticides.

Research use

Versatile reagent in organic synthesis It is used in research laboratories for its ability to react and form new compounds in organic synthesis.

Precaution

Health hazards 2-(4-Methoxyphenyl)-3-oxopropanenitrile can pose health risks if not properly handled and used in controlled environments.

Upstream product

• 104-47-2 p-methoxybenzylnitrile 
• 109-94-4 formic acid ethyl ester 

Downstream Products

• 35070-98-5 5-(4-methoxy-phenyl)-pyrimidine-2,4-diamine 
• 123731-50-0 5,7-dimethoxy-3-(4-methoxyphenyl)-2H-1-benzopyran-2-one 
• 183666-39-9 5-azido-4-(4-methoxyphenyl)isoxazole 
• 19541-95-8 5-amino-3-(4-methoxyphenyl)pyrazole 
• 1039364-83-4 C₁₃H₁₁BrN₄O 
• 93439-79-3 5-amino-4-(4-methoxyphenyl)-1Н-pyrazole 
• 1456789-13-1 3-(4-methoxyphenyl)pyrazolo[1,5-a]quinazolin-5(4H)-one 
• 1456789-28-8 3-(4-methoxyphenyl)-5-(2-dimethylamino-1-ethoxy)pyrazolo[1,5-a]quinazoline hydrochloride 
• 1456789-16-4 5-chloro-3-(4-methoxyphenyl)pyrazolo[1,5-a]quinazolin-5(4H)-one 

Relevant academic research and scientific papers

Catalytic α-monoallylation of aryl acetonitriles

α-Cyano aldehydes undergo selective transition-metal-catalyzed monoallylation to provide α-allylated nitriles. The transformation leads to linear substitution products with palladium catalysts or branched allylated nitriles using an iridium catalyst. Faci

Phenylpyrazolo[1,5-a]quinazolin-5(4 H)-one: A suitable scaffold for the development of noncamptothecin topoisomerase i (Top1) inhibitors

In search for a novel chemotype to develop topoisomerase I (Top1) inhibitors, the pyrazolo[1,5-a]quinazoline nucleus, structurally related to the indenoisoquinoline system precursor of well-known Top1 poisons, was variously decorated (i.e., a substituted

HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK

Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.

Use of Pyrazolo(1,5A)Pyrimidin-7-YL Amine Derivatives in the Treatment of Neurological Disorders

The invention relates to methods of using the compounds of the invention, including pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof, as well as pharmaceutical compositions comprising the same, in the treatment of Eph receptor-related (e.g., neurological) injuries and disorders. The invention also relates to modulating the activity of an Eph receptor in a cell, stimulating neural regeneration, and reversing neuronal degeneration, by administering a compound of the invention to a cell or subject in an effective amount.

PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to certain pyrazolo[1,5-a]pyrimidine compounds, to processes for their preparation, compositions comprising them and methods of using them. The compounds are useful in the treatment of cancer. Novel screening methods are also

Organic compounds

The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.

PYRAZOLO[1,5-A]PYRIMIDIN-7-YL-AMINE DERIVATIVES FOR USE IN THE TREATMENT OF PROTEIN KINASE DEPENDENT DISEASES

The invention relates to the use of pyrazolo[1,5a]pyrimidin-7-yl amine compounds and salts thereof in the treatment of kinase dependent diseases and for the manufacture of pharmaceutical preparations for the treatment of said diseases, novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds, and a process for the preparation of the novel pyrazolo[1,5a]pyrimidin-7-yl amine compounds.

Rates and products from thermolysis of 5-azidoisoxazoles in solution

Thermolysis in solution of 5-azidoisoxazoles with formyl, acetyl or N-phenylimino in the 4-position led to the formation of bicyclic products; in the absence of such 4-substituents, ring-opening resulted and in two instances the expected nitrosoalkene int